12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CM2489: Phase I started

CalciMedica began a blinded, placebo-controlled, U.S. Phase I trial evaluating single ascending-doses of daily oral cm 2489 in...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >